Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment
- PMID: 6814718
- DOI: 10.1007/BF02411260
Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment
Abstract
In 10 patients with Paget's disease of bone and 2 patients with osteoporosis, we studied the effects of hypocalcemia and hypophosphatemia induced by disodium-(3-amino-1-hydroxypropylidene)-1,-bisphosphonate (APD) treatment on the serum concentration of PTH and 1,25-dihydroxy-vitamin D [1,25(OH)2D3] and on calcium absorption and balance. The fall in serum calcium and phosphate was associated with a rise in the serum concentration of PTH and 1,25(OH)2D3, coupled with increases in net calcium absorption and calcium balance. The concentration of 1,25(OH)2D3 was significantly related (P less than 0.001) to the serum calcium (r = 0.66), the serum phosphate (r = 0.78), and the serum PTH (r = 0.71), confirming the interrelated control of these parameters on 1,25(OH)2D3 production. Moreover the rise in 1,25(OH)2D3 caused an appropriate rise in calcium absorption (r = 0.74) and calcium balance (r = 0.86), showing that this vitamin D metabolite contributes as a hormone to calcium homeostasis.
Similar articles
-
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.Calcif Tissue Int. 1982 Jul;34(4):321-7. doi: 10.1007/BF02411261. Calcif Tissue Int. 1982. PMID: 6814719
-
Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.J Bone Miner Res. 1994 Jan;9(1):81-5. doi: 10.1002/jbmr.5650090112. J Bone Miner Res. 1994. PMID: 8154313
-
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.Bone Miner. 1991 Feb;12(2):113-21. doi: 10.1016/0169-6009(91)90040-7. Bone Miner. 1991. PMID: 1849762
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):519-24. doi: 10.1055/s-0031-1284365. Epub 2011 Aug 2. Exp Clin Endocrinol Diabetes. 2011. PMID: 21811962 Review.
Cited by
-
Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model of Distal Nephron Salt Wasting.PLoS One. 2016 Jul 21;11(7):e0159804. doi: 10.1371/journal.pone.0159804. eCollection 2016. PLoS One. 2016. PMID: 27442254 Free PMC article.
-
Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.Drugs. 1991 Feb;41(2):289-318. doi: 10.2165/00003495-199141020-00009. Drugs. 1991. PMID: 1709854 Review.
-
Adverse effects of bisphosphonates. A comparative review.Drug Saf. 1996 Mar;14(3):158-70. doi: 10.2165/00002018-199614030-00003. Drug Saf. 1996. PMID: 8934578 Review.
-
Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.J Bone Miner Metab. 2020 Jul;38(4):501-510. doi: 10.1007/s00774-020-01095-0. Epub 2020 Mar 5. J Bone Miner Metab. 2020. PMID: 32140785
-
Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.Calcif Tissue Int. 1982 Jul;34(4):321-7. doi: 10.1007/BF02411261. Calcif Tissue Int. 1982. PMID: 6814719